NASDAQ:OYST Oyster Point Pharma (OYST) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free OYST Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$11.17▼$11.1750-Day Range$11.08▼$11.2052-Week Range$3.46▼$19.00Volume330 shsAverage Volume212,171 shsMarket Capitalization$299.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Oyster Point Pharma alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Oyster Point Pharma Stock (NASDAQ:OYST)Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Read More Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. OYST Stock News HeadlinesApril 26, 2024 | msn.comWhy Big Pharma Is Following Novartis' Lead In A $25 Billion MarketApril 26, 2024 | theguardian.comReal Americans by Rachel Khong – the lottery of lifeApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 19, 2024 | bizjournals.comAs biotech vacancies hit 20%, oversupply of space could crunch crossover developersApril 15, 2024 | nytimes.comThe 25 Best Restaurants in Boston Right NowApril 3, 2024 | msn.comPortions of Mobile Bay reopen for oyster harvestingMarch 29, 2024 | msn.comThe world is indeed your oyster at the beach in all kinds of waysMarch 28, 2024 | msn.comThe 10 Best Oyster Restaurants In AtlantaApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. March 28, 2024 | msn.comBroad Street Oyster Co.’s Legendary Lobster Rolls Land at Ghirardelli Square TomorrowMarch 24, 2024 | msn.comWhat’s the Best Substitute for Oyster Sauce? We Have 10 Tasty SwapsMarch 9, 2024 | sports.yahoo.comSophomore Bussiere shines in net for Oyster River/Portsmouth in state championship lossMarch 6, 2024 | yahoo.comAww shucks!!! Oyster recycling program reaches major milestoneMarch 5, 2024 | uk.finance.yahoo.comBiotechnology Licensing Deals Analysis Reveals Key Trends and Major Agreements from 2019-2024February 28, 2024 | uk.finance.yahoo.comQ4 2023 Viatris Inc Earnings CallFebruary 22, 2024 | news.yahoo.comOyster River School Board candidate John ColwellFebruary 18, 2024 | thestreet.comOyster Point Pharma Inc.February 16, 2024 | yahoo.comNew restaurant: Grill and oyster bar features burgers, fresh seafood, raw barFebruary 16, 2024 | sports.yahoo.comThursday Seacoast roundup: Oyster River/Portsmouth's Metcalf nets two in girls hockey winFebruary 9, 2024 | yahoo.comWhat Is Oyster Pie?February 8, 2024 | bizjournals.comKilroy's mega project at Oyster Point is facing a 6 month delay. Here's whyJanuary 25, 2024 | msn.comOyster Sales Plummet at LA Restaurants Amid Unclear Guidance From Health OfficialsJanuary 23, 2024 | news.yahoo.comOyster roast helps further land trust missionJanuary 21, 2024 | msn.comPopular Dayton restaurant hosting 8th annual Oyster FestJanuary 20, 2024 | msn.comAvoid All Oysters Imported from Mexico, Health Officials Warn, as Norovirus Cases SpreadJanuary 18, 2024 | yahoo.comRaw oyster illnesses traced to parts of Mexico: Public HealthJanuary 17, 2024 | msn.comRaw Oyster Warning Expanded Across SoCal After Dozens SickenedSee More Headlines Receive OYST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:OYST CUSIPN/A CIK1720725 Webwww.oysterpointrx.com Phone609-382-9032FaxN/AEmployees303Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,660,000.00 Net Margins-901.99% Pretax Margin-901.99% Return on Equity-490.33% Return on Assets-108.29% Debt Debt-to-Equity Ratio8.49 Current Ratio3.35 Quick Ratio3.11 Sales & Book Value Annual Sales$24.54 million Price / Sales12.22 Cash FlowN/A Price / Cash FlowN/A Book Value$3.80 per share Price / Book2.94Miscellaneous Outstanding Shares26,844,000Free Float22,039,000Market Cap$299.85 million OptionableNot Optionable Beta1.31 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jeffrey Nau MMS (Age 47)Ph.D., Pres, CEO & Director Comp: $962.85kMr. Daniel Lochner M.B.A. (Age 40)CFO & Chief Bus. Officer Comp: $642kMr. George Donato M.B.A.Sr. VP of CMC & OperationsDr. Eric Carlson Ph.D.Chief Scientific OfficerArty AhmedVP of Investor relationsMr. Barry Rosenfeld J.D.Sr. VP & Gen. CounselMs. Raegan A. McClain CCEPJ.D., L.L.M., Chief Compliance & Privacy OfficerMs. Karen Castillo-PaffVP of Communications & PRMr. Dave BenadonChief HR OfficerMs. Loni Da Silva M.S.Sr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsAnavex Life SciencesNASDAQ:AVXLMeiraGTxNASDAQ:MGTXOcugenNASDAQ:OCGNMonte Rosa TherapeuticsNASDAQ:GLUEInvivydNASDAQ:IVVDView All Competitors OYST Stock Analysis - Frequently Asked Questions How were Oyster Point Pharma's earnings last quarter? Oyster Point Pharma, Inc. (NASDAQ:OYST) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.48. The business earned $17.94 million during the quarter. Oyster Point Pharma had a negative trailing twelve-month return on equity of 490.33% and a negative net margin of 901.99%. During the same period last year, the firm earned ($0.63) earnings per share. What other stocks do shareholders of Oyster Point Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oyster Point Pharma investors own include OPKO Health (OPK), Pfizer (PFE), Akero Therapeutics (AKRO), Walt Disney (DIS), Energy Transfer (ET), Fulcrum Therapeutics (FULC), Johnson & Johnson (JNJ), Occidental Petroleum (OXY) and vTv Therapeutics (VTVT). When did Oyster Point Pharma IPO? Oyster Point Pharma (OYST) raised $85 million in an initial public offering (IPO) on Thursday, October 31st 2019. The company issued 5,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray acted as the underwriters for the IPO. This page (NASDAQ:OYST) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oyster Point Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
